We are live on
!
Find out more
GCP
GSA Capital Partners Portfolio holdings
AUM
$1.59B
1-Year Est. Return
39.81%
This Fund
S&P 500
This Quarter
Est. Return
-17.67%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$666M
AUM Growth
-$78.6M
(-11%)
Cap. Flow
+$47.8M
Cap. Flow
% of AUM
7.17%
Top 10 Holdings %
Top 10 Hldgs %
3.73%
Holding
1,985
New
628
Increased
360
Reduced
345
Closed
644
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Relay Therapeutics
RLAY
|
+$3.83M |
| 2 |
iShares MSCI Emerging Markets ETF
EEM
|
+$3M |
| 3 |
Teck Resources
TECK
|
+$2.87M |
| 4 |
MODV
ModivCare
MODV
|
+$2.67M |
| 5 |
Genpact
G
|
+$2.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.07M |
| 2 |
CHS
Chicos FAS, Inc.
CHS
|
+$2.68M |
| 3 |
State Street SPDR S&P Regional Banking ETF
KRE
|
+$2.45M |
| 4 |
Crane NXT
CXT
|
+$2.44M |
| 5 |
ATCO
Atlas Corp.
ATCO
|
+$2.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.12% |
| 2 | Technology | 15.11% |
| 3 | Consumer Discretionary | 12.76% |
| 4 | Industrials | 12.53% |
| 5 | Financials | 11.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Herc Holdings
HRI
$5.61B
| $563K | 0.08% |
6,241
-29
| -0.5% | -$3.48K |
|
427
Heron Therapeutics
HRTX
$92.9M
| $562K | 0.08% |
201,424
+53,152
| +36% | +$213K |
|
428
New Fortress Energy
NFE
$101M
| $560K | 0.08% |
+14,147
| New | +$610K |
|
429
BioNTech
BNTX
$23.5B
| $558K | 0.08% |
+3,743
| New | +$572K |
|
430
Royal Gold
RGLD
$19.5B
| $558K | 0.08% |
5,230
+881
| +20% | +$109K |
|
|
DOCU
431
DocuSign
DOCU
$11.5B
| $556K | 0.08% |
9,695
+7,328
| +310% | +$593K |
|
432
EastGroup Properties
EGP
$10.9B
| $555K | 0.08% |
3,598
+2,249
| +167% | +$395K |
|
433
GitLab
GTLB
$6.58B
| $555K | 0.08% |
10,449
+6,522
| +166% | +$303K |
|
434
MGIC Investment
MTG
$6.25B
| $554K | 0.08% |
+43,997
| New | +$579K |
|
435
Darling Ingredients
DAR
$9.44B
| $553K | 0.08% |
+9,255
| New | +$703K |
|
|
AAN
436
DELISTED
The Aaron's Company Inc
AAN
| $553K | 0.08% |
37,978
-75,885
| -67% | -$1.45M |
|
437
Eaton
ETN
$174B
| $552K | 0.08% |
4,381
+2,409
| +122% | +$337K |
|
438
Teladoc Health
TDOC
$1.3B
| $549K | 0.08% |
16,543
+10,764
| +186% | +$457K |
|
439
Allison Transmission
ALSN
$9.82B
| $548K | 0.08% |
14,250
-14,549
| -51% | -$556K |
|
440
BlackLine
BL
$1.72B
| $548K | 0.08% |
+8,233
| New | +$564K |
|
441
Marqeta
MQ
$1.66B
| $548K | 0.08% |
+16,900
| New | +$664K |
|
442
Frontline
FRO
$8.85B
| $547K | 0.08% |
61,689
-88,653
| -59% | -$802K |
|
443
Donnelley Financial Solutions
DFIN
$1.16B
| $546K | 0.08% |
+18,650
| New | +$553K |
|
|
CSII
444
DELISTED
Cardiovascular Systems, Inc.
CSII
| $546K | 0.08% |
38,051
-30,433
| -44% | -$528K |
|
445
Apollo Global Management
APO
$73.4B
| $544K | 0.08% |
11,222
+500
| +5% | +$27.2K |
|
446
PBF Energy
PBF
$7.31B
| $544K | 0.08% |
+18,756
| New | +$587K |
|
447
Workhorse Group
WKHS
$36.3M
| $544K | 0.08% |
70
+63
| +900% | +$594K |
|
448
Ameresco
AMRC
$1.36B
| $541K | 0.08% |
11,868
-20,093
| -63% | -$1.12M |
|
449
Royalty Pharma
RPRX
$25.2B
| $541K | 0.08% |
+12,874
| New | +$528K |
|
450
ManpowerGroup
MAN
$2.63B
| $540K | 0.08% |
7,068
-5,258
| -43% | -$460K |
|
Similar funds
NCL
DG
VNT
SS
GWANC
LCM
LCM
FDCP
GSA Capital Partners's Q2 2022 Portfolio in Review
As of Q2 2022, GSA Capital Partners held 1,985 positions worth $666M, down 11% from $745M the previous quarter. Its ten largest holdings account for 3.7% of the portfolio.
GSA Capital Partners deployed $47.8M of net new capital in Q2 2022, opening 628 new positions and adding to 360 existing holdings. Its largest new stake was Relay Therapeutics: 178,593 shares worth $2.99M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Chicos FAS, Inc., an estimated $2.68M trimmed.
- GSA Capital Partners's largest Q2 2022 buy was Relay Therapeutics: 178,593 shares worth $2.99M.
- GSA Capital Partners added most to Genpact in Q2 2022, an estimated $2.6M increase.
- GSA Capital Partners's biggest Q2 2022 reduction was Chicos FAS, Inc., cutting an estimated $2.68M.
- GSA Capital Partners fully exited Amazon in Q2 2022, selling an estimated $3.07M.
- GSA Capital Partners's ten largest holdings make up 3.7% of its $666M portfolio in Q2 2022.
- GSA Capital Partners opened 628 new positions and closed 644 in Q2 2022.
- GSA Capital Partners's portfolio value fell 11% quarter-over-quarter to $666M.
Based on GSA Capital Partners's 13F filing for Q2 2022, filed 9 Aug 2022.